By David Schwartz, Frank Miskiel and Jennifer Hutchens ( November 6, 2024, 5:45 PM EST) -- On Nov. 8, the U.S. Court of Appeals for the Federal Circuit will hear oral arguments in Teva Branded Pharmaceutical Products R&D v. Amneal Pharmaceuticals of New York. The appeal's central question is whether several of Teva's patents were properly listed in a U.S. Food and Drug Administration publication called Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.